美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · EOLS近 30 天 4 則 · 第 1 / 1 頁
- Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future
- A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
- Telix Appoints David Gill as Chair
- Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
- Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034
- Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
- Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...
- Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
- Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
- Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
- Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
- Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
- 3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80%
- Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。